Looking backward to move forward: a meta-analysis of stem cell therapy in amyotrophic lateral sclerosis

Abstract Transplantation of several types of stem cells (SC) for the treatment of amyotrophic lateral sclerosis (ALS) has been evaluated in numerous Phase I/II clinical trials with inconclusive results. Here, we conducted a meta-analysis to systematically assess the outcome of SC therapy trials whic...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cynthia Morata-Tarifa, Garikoitz Azkona, Jonathan Glass, Letizia Mazzini, Rosario Sanchez-Pernaute
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R
Acceso en línea:	https://doaj.org/article/2fbb57f2b2d8490a838bf471fd9df03c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2fbb57f2b2d8490a838bf471fd9df03c
record_format	dspace
spelling	oai:doaj.org-article:2fbb57f2b2d8490a838bf471fd9df03c2021-12-02T14:25:02ZLooking backward to move forward: a meta-analysis of stem cell therapy in amyotrophic lateral sclerosis10.1038/s41536-021-00131-52057-3995https://doaj.org/article/2fbb57f2b2d8490a838bf471fd9df03c2021-04-01T00:00:00Zhttps://doi.org/10.1038/s41536-021-00131-5https://doaj.org/toc/2057-3995Abstract Transplantation of several types of stem cells (SC) for the treatment of amyotrophic lateral sclerosis (ALS) has been evaluated in numerous Phase I/II clinical trials with inconclusive results. Here, we conducted a meta-analysis to systematically assess the outcome of SC therapy trials which report the evolution of each patient before and after cell administration. In this way, we aimed to determine the effect of the SC intervention despite individual heterogeneity in disease progression. We identified 670 references by electronic search and 90 full-text studies were evaluated according to the eligibility criteria. Eleven studies were included comprising 220 cell-treated patients who received mesenchymal (M) SC (n = 152), neural (N) SC (n = 57), or mononuclear cells (MNC: CD34, CD117, and CD133 positive cells) (n = 11). Our analyses indicate that whereas intrathecal injection of mesenchymal stromal cells appears to have a transient positive effect on clinical progression, as measured by the ALS functional rating score, there was a worsening of respiratory function measured by forced vital capacity after all interventions. Based on current evidence, we conclude that optimal cell product and route of administration need to be determined in properly controlled preclinical models before further advancing into ALS patients. In addition, in-depth understanding of disease mechanisms in subsets of patients will help tailoring SC therapy to specific targets and increase the likelihood of improving outcomes.Cynthia Morata-TarifaGarikoitz AzkonaJonathan GlassLetizia MazziniRosario Sanchez-PernauteNature PortfolioarticleMedicineRENnpj Regenerative Medicine, Vol 6, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R
spellingShingle	Medicine R Cynthia Morata-Tarifa Garikoitz Azkona Jonathan Glass Letizia Mazzini Rosario Sanchez-Pernaute Looking backward to move forward: a meta-analysis of stem cell therapy in amyotrophic lateral sclerosis
description	Abstract Transplantation of several types of stem cells (SC) for the treatment of amyotrophic lateral sclerosis (ALS) has been evaluated in numerous Phase I/II clinical trials with inconclusive results. Here, we conducted a meta-analysis to systematically assess the outcome of SC therapy trials which report the evolution of each patient before and after cell administration. In this way, we aimed to determine the effect of the SC intervention despite individual heterogeneity in disease progression. We identified 670 references by electronic search and 90 full-text studies were evaluated according to the eligibility criteria. Eleven studies were included comprising 220 cell-treated patients who received mesenchymal (M) SC (n = 152), neural (N) SC (n = 57), or mononuclear cells (MNC: CD34, CD117, and CD133 positive cells) (n = 11). Our analyses indicate that whereas intrathecal injection of mesenchymal stromal cells appears to have a transient positive effect on clinical progression, as measured by the ALS functional rating score, there was a worsening of respiratory function measured by forced vital capacity after all interventions. Based on current evidence, we conclude that optimal cell product and route of administration need to be determined in properly controlled preclinical models before further advancing into ALS patients. In addition, in-depth understanding of disease mechanisms in subsets of patients will help tailoring SC therapy to specific targets and increase the likelihood of improving outcomes.
format	article
author	Cynthia Morata-Tarifa Garikoitz Azkona Jonathan Glass Letizia Mazzini Rosario Sanchez-Pernaute
author_facet	Cynthia Morata-Tarifa Garikoitz Azkona Jonathan Glass Letizia Mazzini Rosario Sanchez-Pernaute
author_sort	Cynthia Morata-Tarifa
title	Looking backward to move forward: a meta-analysis of stem cell therapy in amyotrophic lateral sclerosis
title_short	Looking backward to move forward: a meta-analysis of stem cell therapy in amyotrophic lateral sclerosis
title_full	Looking backward to move forward: a meta-analysis of stem cell therapy in amyotrophic lateral sclerosis
title_fullStr	Looking backward to move forward: a meta-analysis of stem cell therapy in amyotrophic lateral sclerosis
title_full_unstemmed	Looking backward to move forward: a meta-analysis of stem cell therapy in amyotrophic lateral sclerosis
title_sort	looking backward to move forward: a meta-analysis of stem cell therapy in amyotrophic lateral sclerosis
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/2fbb57f2b2d8490a838bf471fd9df03c
work_keys_str_mv	AT cynthiamoratatarifa lookingbackwardtomoveforwardametaanalysisofstemcelltherapyinamyotrophiclateralsclerosis AT garikoitzazkona lookingbackwardtomoveforwardametaanalysisofstemcelltherapyinamyotrophiclateralsclerosis AT jonathanglass lookingbackwardtomoveforwardametaanalysisofstemcelltherapyinamyotrophiclateralsclerosis AT letiziamazzini lookingbackwardtomoveforwardametaanalysisofstemcelltherapyinamyotrophiclateralsclerosis AT rosariosanchezpernaute lookingbackwardtomoveforwardametaanalysisofstemcelltherapyinamyotrophiclateralsclerosis
_version_	1718391417981632512

Looking backward to move forward: a meta-analysis of stem cell therapy in amyotrophic lateral sclerosis

Ejemplares similares